Eculizumab 300 mg in 30 mL Injection
RxNorm 700384
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 700384 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: eculizumab 300 mg in 30 mL Injection.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
30 mL eculizumab 10 mg/ML Injection
(Atom ID: 7248486)
PSNPrescribable
Prescribable Name (PSN):
Eculizumab 300 mg in 30 mL Injection
(Atom ID: 7248484)
SYPrescribable
Synonym (SY):
Eculizumab 300 mg per 30 mL Injection
(Atom ID: 7247381)
Patient Education
Eculizumab Injection
Eculizumab injection is used to treat paroxysmal nocturnal hemoglobinuria (PNH: a type of anemia in which too many red blood cells are broken down in the body, so there are not enough healthy cells to bring oxygen to all parts of the body). Eculizumab injection is also used to treat atypical hemolytic uremic syndrome (aHUS; an inherited condition in which small blood clots form in the body and may cause damage to the blood vessels, blood cells, kidneys, and other parts of the body). Eculizumab injection is also used to treat a certain form of myasthenia gravis (MG; a disorder of the nervous system that causes muscle weakness). It is also used to treat neuromyelitis optica spectrum disorder (NMOSD; an autoimmune disorder of the nervous system that affects eye nerves and the spinal cord) in certain adults. Eculizumab injection is in a group of medications called monoclonal antibodies. It works by blocking the activity of the part of the immune system that may damage blood cells in people with PNH and that causes clots to form in people with aHUS. It also works by blocking the activity of the part of the immune system that may damage certain parts of the central nervous system in people with NMOSD or by disrupting communication between nerves and muscles in people with MG.
[Learn More]
* Please review the disclaimer below.